Medicines for Africa
- Startseite
- Schweiz
- Geneva
- Medicines for Africa
We are a social enterprise working on improving access to treatment at a cost that is affordable to people inAfrican countries.
Adresse
33 Ballyclare Drive Ballywoods Office Park, Cedarwood House
Geneva
2191
Öffnungszeiten
| Montag | 09:00 - 17:00 |
| Dienstag | 09:00 - 17:00 |
| Mittwoch | 09:00 - 17:00 |
| Donnerstag | 09:00 - 17:00 |
| Freitag | 09:00 - 17:00 |
Webseite
Benachrichtigungen
Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Medicines for Africa erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.
Kategorie
Our Story
Quality medicines targeting a greater part of societal burden of disease continue to be unaffordable to most African countries and populations. We improve access to medicines of proven quality by all in African countries including the poor.
We are globally connected and locally grounded professionals from multiple disciplines with strong expertise in public health, the global marketplace for medicines, medicines procurement, and supply chains. We share 11 languages with our clients and suppliers, and as a team, we have decades of combined local and international experience in Africa and beyond.
We are passionate and committed to creating value having lived the reality of facing illness without treatment, as millions of people continue to do in African countries. We are deeply committed to solving this social challenge and to delivering value for the people we serve. It is a deep expression of that commitment that we have built MFA on a foundation of strong values and principles that are clearly articulated in various documents that include an MFA Charter, Code of Practice and various internal policies including for managing conflict of interest, rules, procedures and processes such as our Quality Management System and ambition to achieve the relevant ISO certifications.
We reduce the barriers to buying quality medicines at a cost affordable to African countries focusing on a neglected gap in treatments needed by populations outside the priorities of donors.